Details of the Drug

General Information of Drug (ID: DME9QGW)

Drug Name
Marizomib
Synonyms
MARIZOMIB; salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1
Indication
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 3 [1]
Malignant glioma 2A00.0 Phase 1 [2]
Multiple myeloma 2A83 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 313.77
Logarithm of the Partition Coefficient (xlogp) 1.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C15H20ClNO4
IUPAC Name
(1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
Canonical SMILES
C[C@]12[C@H](C(=O)N[C@]1(C(=O)O2)[C@H]([C@H]3CCCC=C3)O)CCCl
InChI
InChI=1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
InChIKey
NGWSFRIPKNWYAO-SHTIJGAHSA-N
Cross-matching ID
PubChem CID
11347535
ChEBI ID
CHEBI:48045
CAS Number
437742-34-2
DrugBank ID
DB11762
TTD ID
D0N0RN
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proteasome (PS) TTU7ZMG NOUNIPROTAC Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03345095) A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (MIRAGE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Triphase Accelerator .
4 Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.